Rumaiza H. Al Yafeai

Rumaiza H. Al Yafeai

Auto-generated profile, based on publicly available information

Rumaiza H. Al Yafeai


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YMYaser Al Malik
Yaser Al Malik
ITIbtisam A. Al Thubaiti
Ibtisam A. Al Thubaiti
MAMaha Alammari
Maha Alammari
NFNorah Al Fugham
Norah Al Fugham
EAEman N. Ali
Eman N. Ali
MJMohammed Al Jumah
Mohammed Al Jumah
For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS) have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS patients are advised to begin treatment with a DMT shortly after diagnosis to limit the possibility of disease progression over time. While patients with radiologically isolated syndrome do not require pharmacologic treatment, high-risk patients with clinically isolated syndrome are advised to start DMTs. This article provides evidence-based recommendations for DMT use in MS management, helping healthcare practitioners advise patients on treatment decisions. We aim to provide recommendations for the management of acute MS relapses. The recommendations herein were developed following the gathering of a panel of experts after evaluating international guidelines, and the latest evidence was collected through a comprehensive literature review.

Verified
Journal Article
Open access
PDF file
JSJameelah A. Saeedi
Jameelah A. Saeedi
RARumaiza H. AlYafeai
Rumaiza H. AlYafeai
AAAbdulaziz M. AlAbdulSalam
Abdulaziz M. AlAbdulSalam
AAAbdulaziz Y. Al-Dihan
Abdulaziz Y. Al-Dihan
AAAzeeza Abdulaziz Aldwaihi
Azeeza Abdulaziz Aldwaihi
MJMohammed Al Jumah
Mohammed Al Jumah
Multiple sclerosis (MS) is an inflammatory neurological illness common in young adults. The prevalence and incidence of MS are regionally and globally increasing. Recent data from Saudi Arabia (SA) estimate the prevalence to be 40.40 cases per 100,000 population, and 61.95 cases per 100,000 population for Saudi nationals. With the increasing availability of treatment options, new challenges for treatment selection and approaches have emerged. There is a clear need for national guidelines to standardize practice, guide the personalization of decisions, and contain increasing costs. A multidisciplinary expert panel was formed to develop evidence-based Saudi consensus recommendations on the diagnosis and clinical care of MS, to aid healthcare practitioners in advising patients on treatment decisions. The recommendations were agreed upon after a thorough review, an evaluation of existing international guidelines, and the latest emerging evidence.

Verified
Journal Article
Open access
PDF file
MAMona Alkhawajah
Mona Alkhawajah
RARayan G. Albarakati
Rayan G. Albarakati
AAAhmed Al-Jedai
Ahmed Al-Jedai
YMYaser Al Malik
Yaser Al Malik
HAHajer Y. Al-Mudaiheem
Hajer Y. Al-Mudaiheem
MJMohammed Al Jumah
Mohammed Al Jumah
This review article addresses the complex issues faced by individuals with Multiple Sclerosis (MS) who are planning a family, becoming pregnant, or wishing to breastfeed their baby. Recommendations and guidelines were discussed and agreed upon by neurologists, neuroradiologists, nurses, and pharmacists involved in the management of MS in the Kingdom of Saudi Arabia (KSA). MS itself does not harm a pregnancy, and people with MS of childbearing age can be encouraged to enjoy family life. Family planning should be a part of the initial conversation with a newly diagnosed patient of childbearing age. Interferons and glatiramer acetate can be continued throughout pregnancy and can be administered during breastfeeding if the benefits outweigh the risks. These DMTs may be considered for a woman with well-controlled MS who is planning a pregnancy or otherwise not using contraception, according to an individualized risk-benefit analysis. The use of contraception should be maintained during the administration of other disease-modifying therapies (DMTs). Natalizumab can be administered at a reduced administration frequency to women with high MS disease activity up to 30 weeks gestation (this agent may induce hematological abnormalities in the fetus). Other DMTs should be withdrawn for variable periods before contraception is stopped and immediately after the discovery of a pregnancy (beware of rebound disease activity after withdrawing natalizumab or fingolimod). Resumption of treatment should not be delayed in women at risk of relapse during the postpartum period and especially in those who do not wish to breastfeed.

Verified
Journal Article
Open access
PDF file
ITIbtisam A. Al Thubaiti
Ibtisam A. Al Thubaiti
MAMona Alkhawajah
Mona Alkhawajah
NFNorah Al Fugham
Norah Al Fugham
DADema Alissa
Dema Alissa
AAAhmed Al-Jedai
Ahmed Al-Jedai
MJMohammed Al Jumah
Mohammed Al Jumah
This article deals with recommendations on the management of symptoms of MS and on the provision of vaccinations in patients receiving disease-modifying therapies (DMTs). Symptoms of MS, such as fatigue, depression, urinary symptoms, spasticity, impairment of gait, and sexual dysfunction, are common in this population. Recognizing and addressing these symptoms is key to maintaining the quality of life of people with MS. Vaccination status should be reviewed and updated prior to initiation of DMTs. In general, vaccination should be avoided for variable periods after the initiation of some DMTs. Live attenuated vaccines are contraindicated and should be considered on a case-by-case basis. These consensus recommendations will present the best practices for vaccination in Saudi Arabia before, during, and after the COVID-19 pandemic. The recommendations will be updated periodically and as needed as new evidence becomes available.